Godbout, K.
Bhutani, M.
Connors, L.
Chan, C. K. N. http://orcid.org/0000-0002-7772-706X
Connors, C.
Dorscheid, D.
Dyck, G.
Foran, V.
Kaplan, A. G.
Reynolds, J.
Waserman, S.
Funding for this research was provided by:
AstraZeneca Canada
Article History
Received: 29 December 2022
Accepted: 2 February 2023
First Online: 17 February 2023
Declarations
:
: Not applicable.
: Not applicable.
: All authors received honoraria for consultancy services on the project from AstraZeneca, in addition: A G Kaplan reports consulting fees or honoraria from AstraZeneca, Bellus, BI, Covis, Cipla, Eisai, GSK, Merck Frosst, Moderna, Novo Nordisk, Pfizer Sanofi, Teva, Trudell, Valeo; Chairperson of Family Physician Airways Group of Canada; Vice president of Respiratory Effectiveness Group. AGK is an honorary professor of primary care Respiratory Research, Observational and Pragmatic Research Institute; Medical director, local pulmonary rehabilitation program; Board member, Thrombosis Canada; Senate member of the International Primary Care Respiratory Group. D Dorshcheid reports grants, contracts, consulting fees, support for travel, or honoraria from Sanofi Regeneron, Novartis Canada, AstraZeneca, GlaxoSmithKline and ValeoPharma. DD is on faculty at the University of British Columbia and is supported by the following grants: Canadian Institutes of Health Research, British Columbia Lung Association, and Michael Smith Foundation for Health Research. DD is an active member of Canadian Thoracic Society, American Thoracic Society, European Respiratory Society, and the Allergen Research Network. K Godbout grants, contracts, consulting fees, support for travel, or honoraria from AstraZeneca, Covis, GSK, TEVA, Valeo and Viatris. M Bhutani reports grants, contracts, consulting fees, support for travel, or honoraria from CIHR, AstraZeneca, GlaxoSmithKline, Novartis, Grifols, Sanofi, Covis, Valeo, Lung Association of Saskatchewan, Canadian Thoracic Society, Lung Association of Alberta and Northwest Territories; leadership roles with Canadian Thoracic Society and Alberta Health Services; Canadian Thoracic Society Executive Committee, Co-Chair of the CTS COPD Clinical Assembly; Chair of the Royal College of Physicians and Surgeons Adult Respiratory Examination. S Waserman reports consulting fees from GSK, Novartis, CSL Behring, Pfizer Canada, Sanofi Canada, AstraZeneca, Takeda, ALK Abello, Teva, Medexus, MiravoHealth, Mylan, Bausch Lomb, AbbVie, Avir Pharma, Leo Pharma,Valeo; research grants from Pfizer Canada, Alk Abello, Aimmune; is current President of Canadian Allergy, Asthma and Immunology Foundation; is currently on the Board of Directors for Asthma Canada. The following authors report no other competing interests: L Connors, CKN Chan<sub>,</sub> C Connors, G Dyck, V Foran, J Reynolds.